Serotonergic psychedelics for depression: A comprehensive overview.
International review of neurobiology 2025 A M Wingert, Claudio Agnorelli, Joseph Peill et al. 1 citation
Depressive disorders continue to pose a major clinical challenge worldwide, particularly given the high prevalence and increasing number of treatment-resistant cases. Over the past decade, advances in research have elucidated the antidepressant potential of psilocybin and other 5-HT₂A receptor agonists in patients with major depressive disorder (MDD) and treatment-resistant depression (TRD)....